There have never been as many new CF drugs in development as there are today. In the second plenary at NACFC, Dr. George Retsch-Bogart outlined the progress we've made, the road ahead and the changes needed to make it all possible. Read on for my key takeaways.
Site Search
I could fill a book with all the things I learned at the virtual North American Cystic Fibrosis Conference this year, but I am especially glad that there was a focus on diversity, gender health, and sex-based differences in CF.
I used to think that genetic-based treatments for cystic fibrosis were mostly theoretical. After watching the first plenary for the North American Cystic Fibrosis Conference, I now know that scientists have a concrete understanding of the work that needs to be done and realistic plans for how to accomplish it.
COVID-19 presented all of us with a great deal of uncertainty. Fortunately, several sessions at the North American Cystic Fibrosis Conference helped provide some data -- and some relief.
In the third plenary, Dr. Peter Mogayzel reminds us of the challenges faced in CF care, the progress we've made, and the work still ahead to meet the needs of all with cystic fibrosis and their families.
Gastrointestinal issues cause serious health and quality-of-life problems for people with cystic fibrosis. That's why it was good to learn about the GI-focused research and care being done.
The recent approval of a game-changing triple-combination therapy and the announcement of a major infusion of research funding are just two reasons why we are at a pivotal time in cystic fibrosis and why this year's North American Cystic Fibrosis Conference in Nashville, Tenn., has been so exciting.
As I listened to the second plenary for this year's North American Cystic Fibrosis Conference, I couldn't help but think of my own experience with CFTR modulators and the positive effects that they have had on my health.
Finding a way to reduce lung inflammation in cystic fibrosis has challenged researchers, but we have made important advances in our understanding of this CF complication in just the last few years. Several drugs also are in development to fight another complication -- the inability to clear mucus from the lungs.
At the third plenary at this year's North American Cystic Fibrosis Conference, we explored what it means to partner in care and how to do it better.